Drug Trial Radar · NCT00048932
A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Nov 24, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,795
Actual
Start
Dec 2002
Primary completion
Oct 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 13, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical research study is to learn if abatacept is safe when co-administered with other approved rheumatoid arthritis medications.
Conditions
- Rheumatoid Arthritis
Interventions
Double-blind AbataceptDrug
Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Day 1, 15, and 29.
Double-blind PlaceboDrug
Concentrate and diluted in a solution, IV, 0 mg, Once daily, Day 1, 15, and 29.
Open-label AbataceptDrug
Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight \> 100 Kg), Once daily, Every 28 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double Blind Period (DB); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to DiscontinuationTime frame: Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication
- DB; Number of Participants With AEs of Special InterestTime frame: Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication
- DB; Number of Participants With Hematology Laboratories Meeting Marked Abnormality CriteriaTime frame: Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication
- DB; Number of Participants With Blood Chemistry Laboratories Meeting Marked Abnormality (MA) CriteriaTime frame: Day 1 to Day 365, and including data up to 56 days post last dose of double-blind medication
- DB; Number of Participants With Clinically Significant Physical Examination or Vital Signs AbnormalitiesTime frame: Days 1, 15, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337. Vital signs were measured at these visits before and after study medication infusion.
- Open Label Period (OL); Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Related AEs, or AEs Leading to DiscontinuationTime frame: Day 365 to Day 1,821
- OL; Number of Participants With AEs of Special InterestTime frame: Day 365 to Day 1821
- OL; Number of Participants With Hematology Laboratories Meeting Marked Abnormality CriteriaTime frame: Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication
- OL; Number of Participants With Liver Function Laboratories Meeting Marked Abnormality CriteriaTime frame: Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication
- OL; Number of Participants With Electrolyte Laboratories Meeting Marked Abnormality CriteriaTime frame: Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication
- OL; Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting Marked Abnormality CriteriaTime frame: Day 365 to Day 1821, and including data up to 56 days post last dose of double-blind medication
- OL; Number of Participants With Clinically Significant Physical Examination or Vital Signs AbnormalitiesTime frame: Days 365 to Day 1821
Locations
44 sites in 1 country. Site status is shown where the registry gives one.
Local Institution
Decatur, Alabama
Local Institution
Paradise, Arizona
Local Institution
Phoenix, Arizona
Local Institution
Tucson, Arizona
Local Institution
San Francisco, California
Local Institution
Loveland, Colorado
Local Institution
Hamden, Connecticut
Local Institution
Lake Worth, Florida
Local Institution
Largo, Florida
Local Institution
Blairsville, Georgia
Local Institution
Chicago, Illinois
Local Institution
Evansville, Indiana
Local Institution
Indianapolis, Indiana
Local Institution
Wichita, Kansas
Local Institution
Louisville, Kentucky
Local Institution
New Orleans, Louisiana
Local Institution
Baltimore, Maryland
Local Institution
Cumberland, Maryland
Local Institution
Westminster, Maryland
Local Institution
Boston, Massachusetts
Local Institution
Grand Rapids, Michigan
Local Institution
Royal Oak, Michigan
Local Institution
Toms River, New Jersey
Local Institution
Los Alamos, New Mexico
Local Institution
New York, New York
Local Institution
Durham, North Carolina
Local Institution
Hickory, North Carolina
Local Institution
Canton, Ohio
Local Institution
Cleveland, Ohio
Local Institution
Columbus, Ohio
Local Institution
Elyria, Ohio
Local Institution
Youngstown, Ohio
Local Institution
Oklahoma City, Oklahoma
Local Institution
Wyomissing, Pennsylvania
Local Institution
Columbia, South Carolina
Local Institution
Sioux Falls, South Dakota
Local Institution
Ducktown, Tennessee
Local Institution
Nashville, Tennessee
Local Institution
Richmond, Virginia
Local Institution
Edmonds, Washington
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.